JPH07509485A - Ovcar−3腺癌細胞治療用医薬及び治療方法 - Google Patents
Ovcar−3腺癌細胞治療用医薬及び治療方法Info
- Publication number
- JPH07509485A JPH07509485A JP6505307A JP50530794A JPH07509485A JP H07509485 A JPH07509485 A JP H07509485A JP 6505307 A JP6505307 A JP 6505307A JP 50530794 A JP50530794 A JP 50530794A JP H07509485 A JPH07509485 A JP H07509485A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino
- onconase
- cisplatin
- phenylalanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (8)
- 1.質量分析法により約12,000ダルトンの分子量又はゲル電気泳動性によ り約14,500ダルトンの分子量を有する蛋白質で、且つ凡そ次の通りのアミ ノ酸組成 モル% アミノ酸残基(24時間酸加水分解) アスパラギン酸/アスパラギン13.39スレオニン9.84 セリン8.08 グルタミン酸/グルタミン5.88 プロリン3.98 グリシン2.98 アラニン2.92 シスチン/27.77 バリン7.77 メチオニン0.94 イソロイシン5.29 ロイシン4.95 チロシン2.85 フェニルアラニン5.73 ヒスチジン2.99 リジン11.78 アルギニン2.85 トリプトファン測定されない 大略総計99.99% を有する蛋白質及び a)シスプラチン、 h)4−〔ビス(2−クロロエチル)アミノ〕−L−フェニルアラニン、又は c)塩酸ドキソルビシンUSP よりなる生物活性な医薬。
- 2.質量分析法により約12,000ダルトンの分子量又はゲル電気泳動法によ る約14,500ダルトンの分子量を有する蛋白質で、且つ凡そ次の通りのアミ ノ酸組成 アミノ酸物質の分子当りの残基の数 アスパラギン酸6 アスパラギン8 スレオニン10 セリン8 グルタミン酸3 ピログルタミン酸1 グルタミン2 プロリン4 グリシン3 アラニン3 シスチン/28 バリン8 メチオニン1 イソロイシン6 ロイシン5 チロジン3 フェニルアラニン6 ヒスチジン3 リジン12 アルギニン3 トリプトファン1 大略合計104 を有する蛋白質及び a)シスプラチン、 b)4−〔ビス(2−クロロエチル)アミノ〕−L−フェニルアラニン、又は c)塩酸ドキソルビシンUSP よりなる生物活性な医薬。
- 3.質量分析法により約12,000ダルトンの分子量、少くとも9.5の等電 点pI及びブロックされたアミノ末端基を有し、本質的に炭水化物を含まない純 粋な蛋白質と a)シスプラチン、 b)4−〔ビス(2−クロロエチル)アミノ〕−L−フェニルアラニン、又は c)塩酸ドキソルビシンUSP の何れかとよりなる生物活性の医薬。
- 4.有力なアミノ酸がりジン及びスレオニンである請求項3の組合せ。
- 5.蛋白質の各分子が確実にトリプトファンの一残基を含む請求項3の組合せ。
- 6.蛋白質の各分子が確実にメチオニンの一残基を含む請求項3の組合せ。
- 7.下記アミノ酸配列、 【配列があります】 を有する蛋白質、並びに a)シスプラチン、 b)4−〔ビス(2−クロロエチル)アミノ〕−L−フェニルアラニン、及び c)塩酸ドキソルビシンUSP よりなる群から選択された化学組成物よりなる生物活性な医薬。
- 8.下記アミノ酸配列 【配列があります】 【配列があります】 を有する蛋白質と a)シスプラチン、 b)4−〔ビス(2−クロロエチル)アミノ〕−L−フェニルアラニン、及び c)塩酸ドキソルビシンUSP よりなる群から選択された化学組成物との治療的活性量を前記蛋白質及び前記化 学物質が腫瘍細胞成長速度を減少するよう患者内で作用するような方法で投与す る段階よりなる患者の腫瘍を治療する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92118092A | 1992-07-30 | 1992-07-30 | |
PCT/US1993/006357 WO1994003197A1 (en) | 1992-07-30 | 1993-07-02 | Pharmaceuticals containing onconase and cisplatin, melphalan and adriamycin |
US921,180 | 1997-08-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07509485A true JPH07509485A (ja) | 1995-10-19 |
JP3655628B2 JP3655628B2 (ja) | 2005-06-02 |
Family
ID=25445040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50530794A Expired - Lifetime JP3655628B2 (ja) | 1992-07-30 | 1993-07-02 | Ovcar−3腺癌細胞治療用医薬及び治療方法 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0656783B1 (ja) |
JP (1) | JP3655628B2 (ja) |
AT (1) | ATE145334T1 (ja) |
DE (1) | DE69306118T2 (ja) |
WO (1) | WO1994003197A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728805A (en) * | 1988-04-06 | 1998-03-17 | Alfacell Corp. | Pharmaceuticals and method for making them |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69006741T2 (de) * | 1989-11-13 | 1994-06-01 | Alfacell Corp | Reines protein und bioaktive pharmazeutische produkte. |
-
1993
- 1993-07-02 WO PCT/US1993/006357 patent/WO1994003197A1/en active IP Right Grant
- 1993-07-02 DE DE69306118T patent/DE69306118T2/de not_active Expired - Lifetime
- 1993-07-02 AT AT93916980T patent/ATE145334T1/de active
- 1993-07-02 EP EP93916980A patent/EP0656783B1/en not_active Expired - Lifetime
- 1993-07-02 JP JP50530794A patent/JP3655628B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1994003197A1 (en) | 1994-02-17 |
DE69306118T2 (de) | 1997-05-15 |
ATE145334T1 (de) | 1996-12-15 |
JP3655628B2 (ja) | 2005-06-02 |
DE69306118D1 (de) | 1997-01-02 |
EP0656783A1 (en) | 1995-06-14 |
EP0656783B1 (en) | 1996-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6961061B2 (ja) | 癌治療のためのadi−peg20抗体に対する交差反応性が低減したアルギニンデイミナーゼ | |
JPH05504566A (ja) | 生物学的活性を有するペプチドを使用した創傷処置方法 | |
EP1369119B1 (en) | Il-12 expression controlling agents | |
JP4848267B2 (ja) | Hcg断片を含む粘膜及び経口投与のための組成物 | |
JP2005521388A5 (ja) | ||
JP6026659B2 (ja) | 神経成長因子が中高年男性の性機能低下症候群を治療するための薬物の調製における応用 | |
Chattong et al. | Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production | |
AU2011211744B2 (en) | Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases | |
US20200147183A1 (en) | Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis | |
JPH07509485A (ja) | Ovcar−3腺癌細胞治療用医薬及び治療方法 | |
AU2004244755B9 (en) | Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds | |
US5529775A (en) | Compositions comprising ONCONASE(™) and cisplatin, melphalan, or doxorubicin HCl | |
JPH03135918A (ja) | 免疫賦活剤 | |
JP5291290B2 (ja) | 化学療法を受けている癌患者の治療方法 | |
US7977320B2 (en) | Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents | |
WO2016097753A1 (en) | Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis | |
CN112543628B (zh) | 含有糖和氨基酸的稳定的输液剂组合物 | |
US20030236189A1 (en) | Two synthetic peptides for treatment and prevention of cancers | |
WO2003020752A1 (fr) | Peptide et produits pharmaceutiques le contenant | |
EP2862577B1 (en) | Use of obestatin for muscle regeneration | |
RU2114611C1 (ru) | Мазь | |
JP2000503668A (ja) | ウリジンからなる神経変性疾患の処置に活性な治療剤 | |
RU2293569C2 (ru) | Способ дозирования препарата миакальцик | |
RU2211046C1 (ru) | Средство, стимулирующее пролиферацию фибробластов | |
JPH0429936A (ja) | 悪性脳腫瘍治療用医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20031222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050304 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080311 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090311 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090311 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100311 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110311 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110311 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120311 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130311 Year of fee payment: 8 |